OncoSil Medical (ASX:OSL) announced early clinical results from Ankara Bilkent City Hospital in Türkiye, demonstrating a potential paradigm shift in the treatment of unresectable locally advanced pancreatic cancer.
In a clinical setting, an unprecedented 83% of patients treated with the OncoSil device alongside standard-of-care chemotherapy underwent surgical resection with curative intent.
The figure outperforms historical benchmarks, which typically report resection rates between 13% and 26% for patients receiving chemotherapy alone.
The OncoSil device is a localised brachytherapy tool that delivers a targeted dose of beta radiation directly into the tumour.
In the Turkish study, post-treatment analysis of the six treated patients showed high therapeutic efficacy: one patient achieved a complete response, four achieved partial responses, and one remained stable.
The ability to "downstage" previously inoperable tumours to a resectable state is critical; clinical data indicates that patients who qualify for surgery nearly double their median overall survival, rising from 16.3 months to 35.3 months.
CEO Nigel Lange described the outcomes as "exceptional," noting that they validate the company's commercial strategy in high-volume treatment centres.
The results surpass even the company's own 2022 PANCO clinical trial, which recorded a 24% resection rate.